1-Methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-imidazole

Catalog No. :
ACFSVX931
CAS No. :
942070-72-6
Molecular Formula :
C10H17BN2O2
Molecular Weight :
208.07

IUPAC Name:1-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-imidazole

1-Methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-imidazole structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
5g95%$62.00Login to see priceIn stockIn stock
25g95%$308.00Login to see priceIn stockIn stock
100g95%$1231.00Login to see priceIn stockInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name1-Methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-imidazole
IUPAC Name1-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-imidazole
MDL No.MFCD11846349
Molecular FormulaC10H17BN2O2
Molecular Weight208.07
SMILESCC1(C)C(C)(C)OB(C2=CN=CN2C)O1
InChI KeySNKPPKAANOYIRX-UHFFFAOYSA-N
SynonymSCHEMBL3282058 | AKOS016007538 | BBL103616 | MFCD11846349 | 1-Methyl-5-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-1h-imidazole | AB64622 | 1-methyl-5-(tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-imidazole | SY014902 | (3-Methylimidazol-4-yl)boronic acid p
CAS No.942070-72-6
PubChem CID25000390

Synthetic Route by SureRoute

1. ACFSVX931 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACTOBU801 route compound structure diagram
    ACTOBU80173183-34-3 In Stock
  2. Plus
  3. ACURKE386 route compound structure diagram
    ACURKE38671759-88-1 In Stock
  4. Then
  5. ACFSVX931 route product structure diagram
    ACFSVX931942070-72-6 In Stock
Inquiry

2. ACFSVX931 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACFSVX931 route product structure diagram
    ACFSVX931942070-72-6 In Stock
Inquiry

Comments (0)